Glenmark Pharmaceuticals Inc., USA is recalling 1,200 bottles of Trandolapril and Verapamil Hydrochloride Extended-Release Tablets (2 mg / 180 mg) because the medication was found to be subpotent during a quality test. This means the tablets may contain less of the active ingredient than specified, which could reduce the medication's effectiveness. The recall affects 100-count bottles from batch number 19224744.
Subpotent medication may not provide the full prescribed dose of the blood pressure treatment. This can lead to poorly controlled blood pressure and associated cardiovascular risks. No injuries or adverse events have been reported to date.
You have 2 options:
Recall #: D-1095-2023; Out of Specification for Assay Test at the 3-month time point.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.